

# Kenneth B Gordon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6867888/publications.pdf>

Version: 2024-02-01

81  
papers

8,722  
citations

101496

36  
h-index

69214

77  
g-index

82  
all docs

82  
docs citations

82  
times ranked

5335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet, The</i> , 2008, 371, 1665-1674.	6.3	1,572
2	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2016, 375, 345-356.	13.9	670
3	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 1318-1328.	13.9	656
4	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 418-431.	0.6	554
5	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	0.6	542
6	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , 2018, 392, 650-661.	6.3	457
7	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 114-135.	0.6	311
8	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , 2018, 379, 1313-1321.	13.9	301
9	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1073-1113.	0.6	281
10	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 136-144.	13.9	270
11	Joint American Academy of Dermatology National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1445-1486.	0.6	184
12	Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. <i>Cancer</i> , 1995, 75, 2169-2173.	2.0	174
13	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1535-1545.	1.3	166
14	A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 304-314.	0.3	157
15	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 241-251.	0.6	157
16	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498.	6.3	139
17	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , 2021, 397, 475-486.	6.3	136
18	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 432-470.	0.6	135

#	ARTICLE	IF	CITATIONS
19	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal of the American Academy of Dermatology, 2020, 82, 161-201.	0.6	129
20	A headâ€“toâ€“head comparison of ixekizumab vs. guselkumab in patients with moderateâ€“toâ€“severe plaque psoriasis: 12â€“week efficacy, safety and speed of response from a randomized, doubleâ€“blinded trial. British Journal of Dermatology, 2020, 182, 1348-1358.	1.4	117
21	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology, 2019, 81, 775-804.	0.6	105
22	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology, 2014, 71, 1176-1182.	0.6	100
23	Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 77-82.e7.	0.6	96
24	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions. JAMA Dermatology, 2018, 154, 676.	2.0	90
25	Maintenance of clinical response and consistent safety profile with up to 3Â“years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. Journal of the American Academy of Dermatology, 2020, 82, 936-945.	0.6	71
26	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. Journal of Investigative Dermatology, 2019, 139, 2437-2446.e1.	0.3	70
27	Anxiety and depression in patients with moderateâ€“toâ€“severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1940-1949.	1.3	62
28	Efficacy of guselkumab in subpopulations of patients with moderateâ€“toâ€“severe plaque psoriasis: a pooled analysis of the phase <sc>III VOYAGE</sc> 1 and <sc>VOYAGE</sc> 2 studies. British Journal of Dermatology, 2018, 178, 132-139.	1.4	57
29	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2016, 375, 2101-2102.	13.9	53
30	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1004-1013.	1.3	52
31	Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Advances in Therapy, 2020, 37, 364-380.	1.3	51
32	Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. Journal of the American Academy of Dermatology, 2017, 76, 1045-1053.e3.	0.6	50
33	Impact of brodalumab treatment on psoriasis symptoms and healthâ€“related quality of life: use of a novel patientâ€“reported outcome measure, the Psoriasis Symptom Inventory. British Journal of Dermatology, 2014, 170, 705-715.	1.4	48
34	Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. British Journal of Dermatology, 2018, 179, 320-328.	1.4	47
35	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis. JAMA Dermatology, 2016, 152, 661.	2.0	46
36	Longâ€“term safety of risankizumab from 17 clinical trials in patients with moderateâ€“toâ€“severe plaque psoriasis*. British Journal of Dermatology, 2022, 186, 466-475.	1.4	41

#	ARTICLE	IF	CITATIONS
37	Serious infections in hospitalized patients with psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 287-296.	0.6	40
38	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.4	36
39	Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2013, 169, 1337-1341.	1.4	32
40	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. <i>Dermatology and Therapy</i> , 2022, 12, 495-510.	1.4	30
41	Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 1344.	2.0	29
42	A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 864-865.	1.3	27
43	Unmet needs in the treatment of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 523-532.	0.3	24
44	The inpatient burden of psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 33-41.	0.6	24
45	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	3.3	24
46	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 294-301.e6.	0.6	22
47	Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 301-309.	1.3	22
48	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 735.	2.0	22
49	Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 219-228.	1.1	17
50	Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 767-776.	1.3	16
51	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. <i>Dermatology</i> , 2021, 237, 46-55.	0.9	16
52	Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. <i>British Journal of Dermatology</i> , 1997, 136, 415-20.	1.4	16
53	The experience of pain and redness in patients with moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 401-405.	1.1	15
54	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021, 184, 652-662.	1.4	15

#	ARTICLE	IF	CITATIONS
55	IL-23 inhibitors for moderate-to-severe psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 158-162.	1.6	14
56	Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. <i>British Journal of Dermatology</i> , 1997, 136, 415-420.	1.4	12
57	Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1297-1304.	1.3	12
58	SAT0130...Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn's disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 514.3-515.	0.5	10
59	Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , 2018, 179, 984-986.	1.4	10
60	Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatology</i> , 2019, 46, 1141-1152.	0.6	9
61	Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 763-768.	1.1	9
62	Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization. <i>Dermatologic Surgery</i> , 1996, 22, 723-8.	0.4	9
63	Patient Satisfaction and Quality of Life in Psoriasis and Psoriatic Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2676.	3.8	8
64	Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2017, 28, 3-7.	1.1	8
65	Efficacy, safety, usability, and acceptability of risankizumab 150mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2085-2093.	1.1	7
66	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. <i>Dermatology and Therapy</i> , 2022, 12, 561-575.	1.4	7
67	Cutaneous Manifestations of Chronic Liver Disease. <i>Clinics in Liver Disease</i> , 2020, 24, 351-360.	1.0	6
68	Risankizumab in moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , 2019, 11, 1357-1370.	1.0	5
69	Understanding Therapeutic Pathways and Comorbidities in Psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S20-S23.	1.6	5
70	Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 1030-1037.	0.6	4
71	Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 147-152.	0.3	2
72	225...An oral, selective inhibitor of tyrosine kinase 2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate to severe psoriasis. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
73	Defining drug-free remission of skin disease in patients with plaque psoriasis. British Journal of Dermatology, 2020, 182, 1484-1487.	1.4	2
74	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Quality of Life Research, 2020, 29, 369-380.	1.5	2
75	Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. Archives of Dermatology, 1997, 133, 691-3.	1.7	2
76	Systemics to topicals in psoriasis: the unfilled need. British Journal of Dermatology, 2013, 169, 2-3.	1.4	1
77	Comparative Effectiveness Studies for Psoriasis—The Methods Matter. JAMA Dermatology, 2020, 156, 253.	2.0	1
78	Update on New and Emerging Therapies in the Management of Psoriasis. Seminars in Cutaneous Medicine and Surgery, 2015, 34, S34-S36.	1.6	1
79	The International Psoriasis Council Presents Top Five Psoriasis Research Articles for July 2010—December 2010. Psoriasis Forum, 2011, 17a, 275-279.	0.1	0
80	Core Outcome Sets for Psoriasis Clinical Trials. JAMA Dermatology, 2018, 154, 1135.	2.0	0
81	FRI0435—INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL. , 2019, , .		0